Company Spotlight: Ribbon Bio

Can you share the story behind Ribbon Bio and what inspired you to focus on the specific challenges your company is addressing in the life sciences sector?

Ribbon Bio was founded to solve one of the core challenges in life sciences: the reliable synthesis of long and accurate DNA molecules. Traditional chemical methods are efficient and cost effective for short sequences, but they become less reliable as the molecules get longer. For scientists, that limitation has been a barrier to progress. At Ribbon we have developed our MiroSynth™ DNA from technology that combines intelligent algorithms, enzymatic assembly, and automation to make long and complex DNA accessible in a short timeframe. The inspiration was simple: to remove a bottleneck that has slowed innovation for too long and give researchers the tools they need to explore ideas that were previously out of reach.

What are the key innovations or technologies that Ribbon Bio is developing, and how do they address unmet needs in the industry?

Our flagship product, MiroSynth™ DNA, is designed to deliver DNA that is longer, more complex, and more accurate than what has previously been possible. Where traditional synthesis struggles with regions of high GC content, homopolymers, or repeats, our technology ensures that even these challenging sequences can be built with precision. More than 90% of our molecules are scarless, adapter free, and 100% sequence accurate. That means scientists spend less time troubleshooting and more time advancing their research. We really focus on providing the industry access to DNA of a quality and scale that enables new discoveries and new applications.

What are some of the biggest challenges you’ve faced as a leader in the biotech space, and how have you navigated them to drive Ribbon Bio’s growth?

One of the biggest challenges has been the transition from a technical stage company to a growth stage company. This requires building a team that can excel not only in science but also in commercialization and execution. I am proud that we have built exactly that kind of team. Over the past two years we have had zero voluntary attrition, and that speaks to the strength of our culture and our shared mission. Navigating this transition has meant making thoughtful choices about where to focus, striking a balance between innovation and execution, and ensuring that our work remains closely aligned with customer needs.

From your perspective, what role does investment play in advancing biotech innovation, and how can the life sciences investment community better support companies like Ribbon Bio?

Investment plays a critical role in biotech because it enables companies to scale technologies that take time and resources to mature. Biotech is capital intensive by nature, but when supported properly it creates breakthroughs that can transform entire industries. For companies like Ribbon, the right investment accelerates the ability to expand capacity, strengthen automation, and build partnerships that bring our technology to more scientists.

The investment community has the power to drive transformative change by taking a long-term view and seeing that foundational technologies are more than incremental improvements—they are the building blocks of the future of life sciences. Too many promising companies stall between scaling and rapid growth; by investing at this critical stage, you can accelerate breakthrough technologies and bring life-changing solutions to market faster.

Looking ahead, what excites you most about the future of Ribbon Bio and the broader life sciences industry? What opportunities do you see on the horizon for innovation and collaboration?

Synthetic biology is only beginning to show its full impact. From healthcare and sustainability to entirely new frontiers like space exploration, the ability to design and build biology is unlocking possibilities that were unimaginable a decade ago. What excites me most is that Ribbon Bio is enabling that progress. By providing access to long and accurate synthetic DNA molecules, we are helping scientists expand the scope of their research and accelerate the pace of innovation. Looking ahead, I see tremendous opportunities to collaborate across industries and with new partners who share our vision of pushing the boundaries of what biology can achieve.

Find out more at: www.ribbonbio.com